CNS Pharmaceuticals, Inc. (CNSP) Stock

Healthcare · Biotechnology · Member of Other US Stocks

CNS Pharmaceuticals, Inc. (CNSP) closed at USD 5.35 on 2026-10-14, a change of -33.6 % over the past year, with a market capitalization of USD 7.57M.

CNS Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

CNS Pharmaceuticals, Inc. key figures

Previous close

USD 5.35 (2026-10-14)

1-year change

-33.6 %

Market cap

USD 7.57M

Enterprise value

USD -12.42M

P/E ratio (trailing)

-0.29

P/E ratio (forward)

-13.28

EPS (trailing)

-17.90

EPS (forward)

-0.39

PEG ratio

n/a

Price to book

0.42

Revenue growth

n/a

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

0.19

Employees

8

Analyst consensus (third-party)

none

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of therapies for neurology and oncology diseases in the United States. It develops TPI 287, an investigational chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma, metastatic breast cancer with brain metastases, non-small cell lung cancer, castration-resistant prostate cancer, and neuroblastoma; and Berubicin, an investigational anthracycline chemotherapy agent, which is in Phase II clinical trial for the treatment of glioblastoma and brain tumors. The company was incorporated in 2017 and is headquartered in Houston, Texas.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for CNS Pharmaceuticals, Inc. and compare it with other stocks.